Trial · NCT05701007
Results by group242
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 242
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Body Mass Index (BMI) | Participants Diagnosed With mCSPC | 27.9 | Standard Deviation 12.4 | Kilogram per meter square | |
| Body Mass Index (BMI) | Participants Diagnosed With mCRPC | 27.1 | Standard Deviation 4.7 | Kilogram per meter square | |
| Prostate-Specific Antigen (PSA) | Participants Diagnosed With mCSPC | 199.7 | Standard Deviation 704.7 | Nanogram per milliliter | |
| Prostate-Specific Antigen (PSA) | Participants Diagnosed With mCRPC | 92 | Standard Deviation 396.4 | Nanogram per milliliter | |
| Alkaline Phosphatase (P-AFOS) | Participants Diagnosed With mCSPC | 214.1 | Standard Deviation 402.3 | Units per liter | |
| Alkaline Phosphatase (P-AFOS) | Participants Diagnosed With mCRPC | 144 | Standard Deviation 221.8 | Units per liter | |
| Length of Follow-up | Participants Diagnosed With mCSPC | 1.8 | Standard Deviation 1.8 | Years | |
| Length of Follow-up | Participants Diagnosed With mCRPC | 1.9 | Standard Deviation 1.6 | Years | |
| Number of Participants With de Novo Metastasis | Participants Diagnosed With mCSPC | 444 | Participants | ||
| Number of Participants With de Novo Metastasis | Participants Diagnosed With mCRPC | 240 | Participants | ||
| Number of Participants Who Received Treatment for mCRPC and mCSPC | Participants Diagnosed With mCSPC | 668 | Participants | ||
| Number of Participants Who Received Treatment for mCRPC and mCSPC | Participants Diagnosed With mCRPC | 536 | Participants | ||
| Number of Participants Diagnosed With mCSPC Who Progressed to mCRPC | Participants Diagnosed With mCSPC | 270 | Participants | ||
| Number of Participants With Orchiectomy | Participants Diagnosed With mCSPC | 10 | Participants | ||
| Number of Participants With Orchiectomy | Participants Diagnosed With mCRPC | 9 | Participants | ||
| Number of Participants Undergone Palliative Radiology | Participants Diagnosed With mCSPC | 222 | Participants | ||
| Number of Participants Undergone Palliative Radiology | Participants Diagnosed With mCRPC | 187 | Participants | ||
| Number of Participants With Symptomatic Skeletal-Related Event (SSRE) | Participants Diagnosed With mCSPC | 44 | Participants | ||
| Number of Participants With Symptomatic Skeletal-Related Event (SSRE) | Participants Diagnosed With mCRPC | 43 | Participants | ||
| Number of Participants With Osteoporosis | Participants Diagnosed With mCSPC | 9 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05701007/results